Phase 2 N=112 ALL Adult Consortium Trial: Adult ALL Trial
Acute Lymphoblastic Leukemia
Primary: Asparaginase Completion Rate — 43; 79 Percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,136 Addressing Obesity in Early Care and Education Settings
Obesity
Primary: Child BMI Z-score — 0.40; 0.43; 0.31; 0.48 Z-score — p=0.003
N/A N=122 An App to Reduce Cannabis Use Among Emerging Adults
Cannabis Use
Primary: App Feasibility — 122 Participants
Phase 4 N=427 Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
HIV
Primary: Number of Participants With High Adherence at Six Months — 36; 40 Participants
N/A N=20 A Culturally Adapted, Social Support-Based, Physical Activity Interventions for South Asian Indian Women in the United States
Sedentary Behavior
Primary: Feasibility as Assessed by the Percentage of Participants Enrolled in the Study — 100 percentage of participants
Phase 3 N=582 A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
Diabetes Mellitus, Type 1
Primary: Change in Glycosylated Haemoglobin (HbA1c) at Week 26 — -0.47; -0.51 Percentage of HbA1c — p=0.0065
N/A N=2,123 Effect of Air Pollution on the Cognitive Function of Adolescents
Attention Impaired · Risk-Taking · Risk Behavior
Primary: Response Speed Consistency Throughout the Attention Network Task-Flanker Task (Post ANT) — 161.3; 160.2 ms — p=0.52
Phase 3 N=243 Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension
Arterial Hypertension
Primary: Number of Subjects With Serum Potassium Levels Below 4.0 mEq/l at Visit 4 — 18; 19; 25; 51 Participants
Phase 3 N=365 Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
Dengue Fever
Primary: Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1]) — 76.8; 88.6…
N/A N=60 EHR Embedded Comparative Effectiveness Studies--WWC
Obesity
Primary: Compliance Rate — 87; 76 percentage of participants
N/A N=20 The Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
Dry Eye Syndrome
Primary: Contrast Sensitivity — -0.375; -0.169; -0.313; -0.264 arbitrary units
Phase 2 N=21 Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Cardiorespiratory Fitness Assessment- Modified Shuttle Walk Test Result — -6.67; -7.63 change shuttles (1 shuttle is 10 meters)
N/A N=154 Anatomical Shoulder™ Inverse/Reverse Study
Cuff-tear Arthropathy
Primary: Functional Performance — 57.9 score on a scale
Phase 3 N=239 Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
N/A N=273 Post Approval Study of the Eversense® Continuous Glucose Monitoring
Diabetes Mellitus · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: The Long-term Safety of the Eversense CGM Systems Over Repeat Insertion and Removal Cycles in the Post-market Setting. — 5; 24; 15 Sensor cycle